FDA Orange Book · active-ingredient family
Regadenoson
Regadenoson: 1 brand, 13 generics; first approved Apr 10, 2008; generic available.
Generic availableHas discontinued products
Generic status & protection
Generic available: 13 ANDA applications approved.
Earliest patent expiry
Brands (NDA)
1
Generics (ANDA)
13
Listed patents
2
Next patent expiry
Feb 02, 2027
in 3 mo
Brand (NDA) products
Originator applications
- ASTELLASNDA 0221612008
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.4MG/5ML (0.08MG/ML) SOLUTION INTRAVENOUS Rx AP
Generic (ANDA) products (13)
Abbreviated applications
- REGADENOSONINDIES PHARMAANDA 2180542024
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.4MG/5ML (0.08MG/ML) SOLUTION INTRAVENOUS Rx AP - REGADENOSONGE HEALTHCAREANDA 2159552024
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.4MG/5ML (0.08MG/ML) SOLUTION INTRAVENOUS Discontinued - - REGADENOSONBAXTER HLTHCARE CORPANDA 2174552023
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.4MG/5ML (0.08MG/ML) SOLUTION INTRAVENOUS Rx AP - REGADENOSONMYLANANDA 2138562023
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.4MG/5ML (0.08MG/ML) SOLUTION INTRAVENOUS Discontinued - - REGADENOSONHIKMAANDA 2158272023
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.4MG/5ML (0.08MG/ML) SOLUTION INTRAVENOUS Rx AP - REGADENOSONEUGIA PHARMAANDA 2164372022
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.4MG/5ML (0.08MG/ML) SOLUTION INTRAVENOUS Rx AP - REGADENOSONHOSPIRAANDA 2143492022
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.4MG/5ML (0.08MG/ML) SOLUTION INTRAVENOUS Rx AP - REGADENOSONGLANDANDA 2073202022
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.4MG/5ML (0.08MG/ML) SOLUTION INTRAVENOUS Rx AP - REGADENOSONIMS LTDANDA 2142522022
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.4MG/5ML (0.08MG/ML) SOLUTION INTRAVENOUS Rx AP - REGADENOSONACCORD HLTHCAREANDA 2132362022
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.4MG/5ML (0.08MG/ML) SOLUTION INTRAVENOUS Rx AP - REGADENOSONAPOTEXANDA 2076042022
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.4MG/5ML (0.08MG/ML) SOLUTION INTRAVENOUS Rx AP - REGADENOSONDR REDDYSANDA 2132102022
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.4MG/5ML (0.08MG/ML) SOLUTION INTRAVENOUS Rx AP - REGADENOSONMEITHEALANDA 2128062022
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.4MG/5ML (0.08MG/ML) SOLUTION INTRAVENOUS Rx AP
Patent & exclusivity timeline
Protection horizon
Patent expiryExclusivity endToday
Listed patents
Orange Book patent file
| Patent | Expires | In | Type |
|---|---|---|---|
| 8106183 | in 3 mo | Substance | |
| RE47301 | in 3 mo | Product |
Approval history
FDA approval span
First approval
18 yr 10 mo ago
Most recent approval
2 yr 2 mo ago
Approvals span 2008–2024 across 14 FDA applications.
Brand (NDA) 17%
Generic (ANDA) 1393%
Regadenoson: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Assyro Intelligence
Ask anything about Regadenoson
Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.
Evaluating for a team? Book a demo